nach oben

01.01.2014 | ORPHAN DISEASES (B MANGER, SECTION EDITOR)

Mucopolysaccharidoses

verfasst von: Rolando Cimaz, Francesco La Torre

Erschienen in: Current Rheumatology Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The mucopolysaccharidoses (MPSs) are a group of rare genetic disorders of glycosaminoglycan catabolism, caused by a deficiency of lysosomal enzymes required for GAG degradation. Incomplete breakdown of glycosaminoglycans leads to progressive accumulation of these substances in many tissues throughout the body. Different residual enzymatic activity can result in different phenotypes of the same MPS disorder, from severe to attenuated. Musculoskeletal manifestations are common across all forms of MPS. Skeletal and joint abnormalities are prominent features of many MPS disorders, particularly attenuated phenotypes. However, diagnostic delays occur frequently for patients with an MPS, especially those with more attenuated forms of disease. In the absence of appropriate treatment, these conditions are chronic, progressive and often debilitating, but treatment for many types of MPS is now available. Therefore, increasing awareness of MPS among rheumatologists is extremely important.

1.••

Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v4–12. An excellent overview of the MPS disorders emphasising pathophysiology, diagnosis, and treatment options.CrossRef

Neufeld EU, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. New York: McGraw–Hill; 2001. p. 3421–52.

Tomatsu S, Okamura K, Maeda H, et al. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 2005;28:187–202.PubMedCrossRef

Tomatsu S, Gutierrez MA, Ishimaru T, et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis. 2005;28:743–57.PubMedCrossRef

Federico A, Capece G, Cecio A, et al. Sanfilippo B syndrome (MPS III B): case report with analysis of CSF mucopolysaccharides and conjunctival biopsy. J Neurol. 1981;225:77–83.PubMedCrossRef

Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A. 2008;146A:2538–44.PubMedCrossRef

Tuschl K, Gal A, Paschke E, et al. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol. 2005;32:270–2.PubMedCrossRef

Sukegawa K, Matsuzaki T, Fukuda S, et al. Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation. Clin Genet. 1998;53:96–101.PubMedCrossRef

Schulze-Frenking G, Jones SA, Roberts J, et al. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis. 2011;34:203–8.PubMedCentralPubMedCrossRef

10.

Cimaz R, Vijay S, Haase C, et al. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin Exp Rheumatol. 2006;24(2):196–202.PubMed

11.••

Morishita K, Petty RE. Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v19–25. A comprehensive review of clinical rheumatological aspects of MPS patients.CrossRef

12.

Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94:872–7.PubMedCrossRef

13.

Cudry S, Tigaud I, Froissart R, et al. MPS II in females: molecular basis of two different cases. J Med Genet. 2000;37:E29.PubMedCrossRef

14.

Peters C. Hematopoietic cell transplantation for storage diseases. In: Blume KG, Forman SJ, Appelbaum FR, editors. Hematopoietic stem cell transplantation. Malden: Blackwell Science; 2004. p. 1455–70.

15.

McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age—a sibling control study. Clin Genet. 2010;77:492–8.PubMedCrossRef

16.

Manger B. Rheumatological manifestations are key in the early diagnosis of mucopolysaccharidosis type I. Eur Musculoskelet Rev. 2008;1–6.

17.

Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed

18.

Cimaz R, Coppa GV, Kone-Paut I, et al. Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis. Pediatr Rheumatol Online J. 2009;7:18.PubMedCentralPubMedCrossRef

19.

Aldenhoven M, Sakkers RJ, Boelens J, et al. Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis. 2009;68:1659–65.PubMedCrossRef

20.

Pastores GM, Meere PA. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler–Scheie syndrome (mucopolysaccharidosis type 1). Curr Opin Rheumatol. 2005;17:70–8.PubMedCrossRef

21.

Del Rosso A, Matucci-Cerinic M, De Giorgio F, et al. Rheumatological manifestations in diabetes mellitus. Curr Diabetes Rev. 2006;2:455–66.

22.•

Thomas JA, Beck M, Clarke JT, et al. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis. 2010;33:421–7. This paper reveals the characteristics of the most frequent attenuated form of MPS disorders: Scheie syndrome.PubMedCentralPubMedCrossRef

23.

White KK, Karol LA, White DR, et al. Musculoskeletal manifestations of Sanfilippo syndrome (mucopolysaccharidosis type III). J Pediatr Orthop. 2011;31:594–8.PubMedCrossRef

24.

Link B, de Camargo Pinto LL, Giugliani R, et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop Rev. 2010;2:e16.CrossRef

25.

Al-Qatan MM, Thomson HG, Clarke HM. Carpal tunnel syndrome in children and adolescents with no history of trauma. J Hand Surg. 1996;21B:108–11.CrossRef

26.

Yuen A, Dowling G, Johnstone B, et al. Carpal tunnel syndrome in children with mucopolysaccaridoses. J Child Neurol. 2007;22:260–3.PubMedCrossRef

27.

Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg. 1998;23A:236–43.CrossRef

28.

MacDougal B, Weeks PM, Wray RC. Median nerve compression and trigger finger in the mucopolysaccharidoses and related diseases. Plast Reconstr Surg. 1977;59:260–3.PubMed

29.

Maurer K, Fenske A, Samii M. Carpal tunnel syndrome combined with trigger finger in early childhood. J Neurol Neurosurg Psychiatry. 1980;3:1148.CrossRef

30.

Haddad FS, Hill RA, Jones DH. Triggering in the mucopolysaccharidoses. J Pediatr Orthop B. 1998;7:138–40.PubMedCrossRef

31.

Kim HR, Lee SH. Ultrasonographic assessment of clinically diagnosed trigger fingers. Rheumatol Int. 2010;30:1455–8.PubMedCrossRef

32.

Serafini G, Derchi LE, Quadri P, et al. High resolution sonography of the flexor tendons in trigger fingers. J Ultrasound Med. 1996;15:213–9.PubMed

33.

Ryzewicz M, Wolf JM. Trigger digits: principles, management, and complications. J Hand Surg [Am]. 2006;31:135–46.CrossRef

34.

Pastores GM. Musculoskeletal complications encountered in the lysosomal storage disorders. Best Pract Res Clin Rheumatol. 2008;22:937–47.PubMedCrossRef

35.

Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest. 2001;81:1319–28.PubMedCrossRef

36.

Simonaro CM, D’Angelo M, Haskins ME, Schuchman EH. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res. 2005;57:701–7.PubMedCrossRef

37.

Simonaro CM, D’Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease:implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2008;172:112–22.PubMedCrossRef

38.

Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6:489–506.PubMedCrossRef

39.

Schmidt H, Ullrich K, von Lengerke HJ, et al. Radiological findings in patients with mucopolysaccharidosis I H/S (Hurler–Scheie syndrome). Pediatr Radiol. 1987;17:409–14.PubMedCrossRef

40.

Chen SJ, Li YW, Wang TR, Hsu JC. Bony changes in common mucopolysaccharidoses. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1996;37:178–84.PubMed

41.

Tandon V, Williamson JB, Cowie RA, et al. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br. 1996;78:938–44.PubMedCrossRef

42.

Weisstein JS, Delgado E, Steinbach LS, et al. Musculoskeletal manifestations of Hurler syndrome:long-term follow-up after bone marrow transplantation. J Pediatr Orthop. 2004;24:97–101.PubMedCrossRef

43.••

White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v26–33. A comprehensive review of orthopedic aspects of MPS disorders.CrossRef

44.

Field RE, Buchanan JA, Copplemans MG, et al. Bone-marrow transplantation in Hurler’s syndrome. Effect on skeletal development. J Bone Joint Surg Br. 1994;76:975–81.PubMed

45.

White KK, Steinman S, Mubarak SJ. Cervical stenosis and spastic quadriparesis in morquio disease (MPS IV). A case report with twenty-six-year follow-up. J Bone Joint Surg Am. 2009;91:438–42.PubMedCrossRef

46.

Kanazawa T, Yasunaga Y, Ikuta Y, et al. Femoral head dysplasia in Morquio disease type A: bilateral varus osteotomy of the femur. Acta Orthop Scand. 2001;72:18–21.PubMedCrossRef

47.

Taylor C, Brady P, O’Meara A, et al. Mobility in Hurler syndrome. J Pediatr Orthop. 2008;28:163–8.PubMedCrossRef

48.

Montano AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165–74.PubMedCrossRef

49.

Odunusi E, Peters C, Krivit W, et al. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop. 1999;19:270–4.PubMed

50.

De Waal Malefijt MC, van Kampen A, van Gemund JJ. Total knee arthroplasty in patients with inherited dwarfism _a report of five knee replacements in two patients with Morquio’s disease type A and one with spondylo-epiphyseal dysplasia. Arch Orthop Trauma Surg. 2000;120:179–82.PubMedCrossRef

51.

Pizzutillo PD, Osterkamp JA, Scott Jr CI, Lee MS. Atlantoaxial instability in mucopolysaccharidosis type VII. J Pediatr Orthop. 1989;9:76–8.PubMedCrossRef

52.

Thomas SL, Childress MH, Quinton B. Hypoplasia of the odontoid with atlanto-axial subluxation in Hurler’s syndrome. Pediatr Radiol. 1985;15:353–4.PubMedCrossRef

53.

Brill CB, Rose JS, Godmilow L, et al. Spastic quadriparesis due to C1–C2 subluxation in Hurler syndrome. J Pediatr. 1978;92:441–3.PubMedCrossRef

54.

Kacher E, Maestro RD. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery. 2000;47:223–8.

55.

Paulson GW, Meagher JN, Burkhart J. Spinal pachymeningitis secondary to mucopolysaccharidosis. J Neurosurg. 1974;41:618–21.PubMedCrossRef

56.

Balani KG, Krivit W, Carpenter BL, et al. Children with mucopolysaccharidosis: perioperative care, morbidity, mortality and new findings. J Pediatr Surg. 1993;28:403–8.CrossRef

57.

Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio’s disease). Further evidence for heterogeneity. Part III: odontoid dysplasia. Clin Genet. 1988;33:126–30.PubMedCrossRef

58.

Mikles M, Stanton RP. A review of Morquio syndrome. Am J Orthop. 1997;26:533–40.PubMed

59.

Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996;19:357–65.PubMedCrossRef

60.

Silveri CP, Kaplan FS, Fallon MD, et al. Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop. 1991;269:305–11.PubMed

61.

Polgreen LE, Miller BS. Growth patterns and the use of growth hormone in the mucopolysaccharidoses. J Pediatr Rehabil Med. 2010;3:25–38.PubMedCentralPubMed

62.

Scheie HG, Hambrick Jr GW, Barness LA. A newly recognized forme fruste of Hurler’s disease (gargoylism). Am J Ophthalmol. 1962;53:753–69.PubMed

63.

Vieira T, Schwartz I, Munoz V et al. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet A. 2008;146A(13):1741–47.

64.

Arn P, Wraith JE, Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J Pediatr. 2009;154(6):859–864.

65.

Mahalingam K, Janani S, Priya S, et al. Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives. Indian J Pediatr. 2004;71:29–32.PubMedCrossRef

66.

Hall CW, Liebaers I, Di Natale P, Neufeld EF. Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol. 1978;50:439–56.PubMed

67.

Young EP. Prenatal diagnosis of Hurler disease by analysis of alpha–iduronidase in chorionic villi. J Inherit Metab Dis. 1992;15:224–30.PubMedCrossRef

68.

Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics. 2011;5:156–69.PubMedCentralPubMedCrossRef

69.

Gelb MH, Turecek F, Scott CR, Chamoles NA. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006;29:397–404.PubMedCentralPubMedCrossRef

70.

Meikle PJ, Grasby DJ, Dean CJ, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006;88:307–14.PubMedCrossRef

71.

De Ruijter J, de Ru MH, Wagemans T, et al. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. Mol Genet Metab. 2012;107(4):705–10.PubMedCrossRef

72.

Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2013. doi:10.1016/j.ymgme.2013.06.007.

73.

Souillet G, Guffon N, Maire I, et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31:1105–17.PubMedCrossRef

74.

Herskhovitz E, Young E, Rainer J, et al. Bone marrow transplantation for Maroteaux–Lamy syndrome (MPS VI):long-term follow-up. J Inherit Metab Dis. 1999;22:50–62.PubMedCrossRef

75.

Yamada Y, Kato K, Sukegawa K. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 1998;21:629–34.PubMedCrossRef

76.

Braunlin EA, Stauffer NR, Peters CH, et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003;92:882–6.PubMedCrossRef

77.

Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol. 2010;47:59–69.PubMedCrossRef

78.

Boelens JJ, Wynn RF, O’Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–33.PubMedCrossRef

79.

Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5.PubMedCentralPubMedCrossRef

80.

Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120:e37–46.PubMedCrossRef

81.

Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229–40.PubMedCrossRef

82.

Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465–73.PubMedCrossRef

83.

Harmatz P, Giugliani R, Schwartz I, MPS VI Study Group, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533–9.PubMedCrossRef

84.

Muenzer J, Beck M, Eng CM, et al. Long-term, open labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95–101.PubMedCrossRef

85.

Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med. 2011;13:102–9.PubMedCrossRef

86.

Mendelsohn NJ, Harmatz P, Bodamer O, Hunter Outcome Survey Investigators, et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med. 2010;12:816–22.PubMedCrossRef

87.••

Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v49–59. An excellent review of treatment options for MPS disorders.CrossRef

Titel: Mucopolysaccharidoses
verfasst von: Rolando Cimaz
Francesco La Torre
Publikationsdatum: 01.01.2014
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 1/2014
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-013-0389-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen